Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study

Conclusion At 24 months, frequencies of relapse did not differ between the groups, and SAEs were less frequent in the reduced-dose group due to the lower event rate in the 6-month induction phase. The bias to myeloperoxidase-ANCA positivity (85.8%) in the trial population should be noted. Trial registration number NCT02198248.

http://ard.bmj.com/cgi/content/short/83/1/96?rss=1

Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Furuta, S., Nakagomi, D., Kobayashi, Y., Hiraguri, M., Sugiyama, T., Amano, K., Umibe, T., Kono, H., Kurasawa, K., Kita, Y., Matsumura, R., Kaneko, Y., Ninagawa, K., Hiromura, K., Kagami, S.-i., Inaba, Y., Hanaoka, H., Ikeda, K., Nakajima, H., for the LoV Tags: ARD Lay summaries, ARD, Vasculitis Source Type: research